133025-92-0

Basic information

• Product Name: 2-[4-(2-AMINO-ETHYL)-PHENOXY]-N,N-DIETHYL-ACETAMIDE
• Synonyms: 2-[4-(2-AMINO-ETHYL)-PHENOXY]-N,N-DIETHYL-ACETAMIDE
• CAS NO: 133025-92-0
• Molecular Formula: C₁₄H₂₂N₂O₂
• Molecular Weight: 250.34
• Mol File: 133025-92-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-[4-(2-AMINO-ETHYL)-PHENOXY]-N,N-DIETHYL-ACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[4-(2-AMINO-ETHYL)-PHENOXY]-N,N-DIETHYL-ACETAMIDE(133025-92-0)
• EPA Substance Registry System: 2-[4-(2-AMINO-ETHYL)-PHENOXY]-N,N-DIETHYL-ACETAMIDE(133025-92-0)

Safety Data

• Hazardous Substances Data: 133025-92-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
2-[4-(2-AMINO-ETHYL)-PHENOXY]-N,N-DIETHYL-ACETAMIDE is used as a potential drug candidate in pharmaceutical research for its unique structure and properties. Its phenoxy, aminoethyl, and diethyl groups may contribute to its potential therapeutic effects in treating various medical conditions.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 2-[4-(2-AMINO-ETHYL)-PHENOXY]-N,N-DIETHYL-ACETAMIDE is used for its potential applications in the development of therapeutic agents. Its structure and properties make it a valuable compound for further research and exploration in drug discovery.
Used in Drug Discovery:
2-[4-(2-AMINO-ETHYL)-PHENOXY]-N,N-DIETHYL-ACETAMIDE is utilized in drug discovery processes to identify its potential as a therapeutic agent. Its unique chemical structure and properties may offer new avenues for the development of innovative treatments for various medical conditions.

Upstream product

• 29655-46-7 N-benzyloxycarbonyl-2-(4-hydroxyphenyl)ethylamine 
• 51-67-2 tyrosamine 
• 245078-44-8 N,N-diethyl-2-(4-(2-N-benzyloxycarbamyllethyl)phenoxy)acetamide 

Downstream Products

• 46843-08-7 N,N-diethyl-2-(4-(2-aminoethyl)phenoxy)ethylamine 

Relevant articles and documents

Structure-activity relationship of N-(phenylalkyl)cinnamides as novel NR2B subtype-selective NMDA receptor antagonists

A novel series of N-(phenylalkyl)cinnamides related to N-(4- phenylbutyl)-3,4-dihydroxy-β-cyanocinnamide (6, an EGFR-K inhibitor with high antiproliferative activity) was synthesized and tested for antagonism at N-methyl-D-aspartate (NMDA) receptor subtypes. Potency and subunit selectivity were assayed by electrical recordings in Xenopus oocytes expressing three binary combinations of cloned rat NMDA receptor subunits: NR1A expressed in combination with either NR2A, NR2B, or NR2C. The N- (phenylalkyl)cinnamides are selective antagonists of NR1(A)/2B receptors. Assayed under steady-state conditions, N-(4-phenylbutyl)-4-hydroxycinnamide (16) has an IC50 value of 77 nM and > 1000-fold selectivity with respect to NR1(A)/2A and NR1(A)/2C receptors. Potency at α1 adrenergic receptors is low for the four cinnamides tested. Inhibition of NR1(A)/2B receptors does not correlate with EGFR and ErbB2/neu tyrosine kinase inhibitor activity. The N-(phenylalkyl)cinnamide series we describe provides a novel and structurally diverse framework for designing new NR2B-selective NMDA antagonists as potential CNS therapeutics.